EOLS Q3 2020 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$338M

Q3 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$18M+34.1% YoY

Gross Profit

$11M62.6% margin

Operating Income

-$11M-63.6% margin

Net Income

-$11M-64.9% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

+126.2%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$216M

Total Liabilities

$181M

Stockholders' Equity

$35M

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$13M	+34.1%
Gross Profit	$11M	$9M	+17.1%
Operating Income	-$11M	-$25M	+55.3%
Net Income	-$11M	-$27M	+57.5%

Revenue Segments

Product

$17M100%

Geographic Segments

CANADA

$738,000100%